Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. PDX models are used to create an environment that allows for the natural growth of cancer, its monitoring, and corresponding treatment evaluations for the original patient.
Scope of the Report:
This report studies the Patient Derived Xenograft/PDX Models market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Patient Derived Xenograft/PDX Models market by product type and applications/end industries.
Several types of immunodeficient mice can be used to establish PDX models: athymic nude mice, severely compromised immune deficient (SCID) mice, NOD-SCID mice, and recombination-activating gene 2 (Rag2)-knockout mice. The mice used must be immunocompromised to prevent transplant rejection. The NOD-SCID mouse is considered more immunodeficient than the nude mouse, and therefore is more commonly used for PDX models because the NOD-SCID mouse does not produce natural killer cells.
The global Patient Derived Xenograft/PDX Models market is valued at xx million in 2017 and is expected to reach xx million by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Patient Derived Xenograft/PDX Models.
Europe also play important roles in global market, with market size of xx million in 2017 and will be xx million in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Crown Bioscience
The Jackson Laboratory
Champions Oncology
Charles River Laboratories
WuXi Apptec
Oncodesign
Horizon Discovery
Pharmatest Services
Hera Biolabs
EPO Berlin-Buch
Xentech
Urolead
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Mice Models
Rat Models
Market Segment by Applications, can be divided into
Pre-clinical Drug Development and Basic Cancer Research
Biomarker Analysis
Scope of the Report:
This report studies the Patient Derived Xenograft/PDX Models market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Patient Derived Xenograft/PDX Models market by product type and applications/end industries.
Several types of immunodeficient mice can be used to establish PDX models: athymic nude mice, severely compromised immune deficient (SCID) mice, NOD-SCID mice, and recombination-activating gene 2 (Rag2)-knockout mice. The mice used must be immunocompromised to prevent transplant rejection. The NOD-SCID mouse is considered more immunodeficient than the nude mouse, and therefore is more commonly used for PDX models because the NOD-SCID mouse does not produce natural killer cells.
The global Patient Derived Xenograft/PDX Models market is valued at xx million in 2017 and is expected to reach xx million by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Patient Derived Xenograft/PDX Models.
Europe also play important roles in global market, with market size of xx million in 2017 and will be xx million in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Crown Bioscience
The Jackson Laboratory
Champions Oncology
Charles River Laboratories
WuXi Apptec
Oncodesign
Horizon Discovery
Pharmatest Services
Hera Biolabs
EPO Berlin-Buch
Xentech
Urolead
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Mice Models
Rat Models
Market Segment by Applications, can be divided into
Pre-clinical Drug Development and Basic Cancer Research
Biomarker Analysis
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
